The US Food and Drug Administration has accepted United Therapeutics Corporation’s (NASDAQ: UTHR) New Drug Application for ralinepag in pulmonary arterial hypertension and set a PDUFA target action date of June 24, 2027, moving a once-daily oral prostacyclin IP-receptor agonist into formal regulatory review after one of the largest event-driven trials conducted in contemporary PAH treatment. Ralinepag remains investigational and has not been approved for any indication. If authorized, United Therapeutics says it would become the first once-daily oral prostacyclin-pathway therapy, potentially offering another route to intensify treatment without requiring infusion therapy or more frequent oral dosing.
The filing rests principally on ADVANCE OUTCOMES, a randomized, double-blind and placebo-controlled Phase 3 trial in which 687 patients were included in the full efficacy and safety analysis. A first clinical worsening event occurred in 64 of 350 ralinepag-treated participants, or 18%, compared with 121 of 337 placebo recipients, or 36%, producing a hazard ratio of 0.45 and a 55% relative reduction in risk. Importantly, nearly 80% of participants were already receiving dual background PAH therapy, making the result a test of treatment intensification rather than ralinepag simply outperforming minimal therapy.
Why does a 55% reduction in clinical worsening matter more than a short-term exercise test?
PAH is a progressive pulmonary vascular disease that places increasing pressure on the right side of the heart and can eventually result in right-heart failure and death. Earlier clinical development often relied heavily on six-minute walk distance because it provides a relatively rapid measure of functional improvement. Modern PAH trials increasingly use longer-term clinical worsening composites because the more consequential objective is delaying deterioration, hospitalization, escalation to more intensive therapy or death rather than simply allowing patients to walk farther over several months.
ADVANCE OUTCOMES was deliberately event driven and followed patients for a median of approximately 85 weeks in the ralinepag group and 78.4 weeks in the placebo group. Its composite included death, hospitalization for worsening PAH or right-heart failure, initiation of parenteral or inhaled prostacyclin therapy, disease progression and unsatisfactory long-term clinical response. That structure makes the 0.45 hazard ratio clinically more informative than a trial based exclusively on short-term exercise capacity.
The composition of those events also deserves scrutiny. The largest numerical differences between ralinepag and placebo came from disease progression, initiation of parenteral or inhaled prostacyclin therapy and unsatisfactory long-term clinical response. American College of Cardiology reviewers noted no meaningful difference in the death or hospitalization components individually. The drug therefore demonstrated a strong overall effect on worsening, but the current trial does not establish a mortality benefit.
What did ralinepag add when most participants were already receiving two PAH medicines?
Approximately 80% of the full analysis population was receiving dual background PAH therapy, and about 70% was in WHO functional class II at baseline. That creates an increasingly relevant clinical population because modern PAH treatment frequently begins with combination therapy rather than waiting for one medicine to fail before another is added.
Ralinepag still produced measurable improvements beyond the clinical-worsening endpoint. NT-proBNP fell by 24.3% relative to placebo at week 28, while six-minute walk distance improved by a placebo-corrected 20.4 meters. The odds of achieving a broader definition of clinical improvement increased by 47%. Taken together, the findings indicate activity across disease progression, cardiac-stress biomarker and exercise-capacity measures rather than dependence on one unusually favorable endpoint.
The results could support earlier use of prostacyclin-pathway therapy if physicians perceive once-daily oral dosing as more manageable than infusion or inhaled treatment. Whether FDA labeling and subsequent guidelines position ralinepag broadly across treated PAH or more selectively will depend on the complete benefit-risk review.
Why is ralinepag different from simply giving more conventional prostacyclin?
Ralinepag is a selective non-prostanoid agonist of the prostacyclin IP receptor. Activating that receptor increases intracellular cyclic AMP in pulmonary vascular cells, supporting vasodilation and signaling associated with reduced vascular smooth-muscle proliferation. United Therapeutics has reported higher in-vitro receptor affinity and cAMP potency than MRE-269, the active metabolite of selexipag, although laboratory pharmacological differences should not be interpreted automatically as proof of superior clinical efficacy between the medicines.
Its practical differentiation is prolonged oral exposure supporting once-daily dosing. Parenteral prostacyclin therapies can be highly effective but impose substantial treatment complexity through continuous infusion systems, while other oral pathway therapies require different dosing schedules and titration approaches.
ADVANCE OUTCOMES suggests that further prostacyclin-pathway intensification can provide benefit even after patients have already accumulated substantial background therapy. The regulatory review now has to decide whether the efficacy and dosing advantages sufficiently outweigh the tolerability burden.
Why could the 19% discontinuation rate become a meaningful part of the FDA assessment?
Adverse events caused 65 of 350 ralinepag-treated patients, or 19%, to discontinue treatment compared with 10 of 337 placebo patients, or 3%. Headache, diarrhea, nausea and myalgia were among the most frequently reported adverse effects and are broadly consistent with prostacyclin-pathway pharmacology. Serious adverse events occurred in 28% of ralinepag patients and 31% of placebo patients, while adverse events leading to death occurred in 4% of each group.
The timing matters because discontinuation was particularly frequent during titration, according to the ACC review. Prostacyclin therapies often require careful dose escalation as physicians attempt to reach a biologically useful exposure while managing vasodilatory and gastrointestinal effects. A once-daily tablet simplifies administration, but it does not eliminate mechanism-related tolerability.
Clinical adoption will therefore depend partly on whether physicians can develop titration protocols that preserve the trial’s long-term efficacy while reducing early attrition. A medicine cannot deliver durable disease modification to a patient who cannot remain on it.
Could ralinepag delay the need for infused or inhaled prostacyclin therapy?
That possibility is embedded directly in the Phase 3 endpoint. Initiation of parenteral or inhaled prostacyclin-pathway treatment was one of the clinical-worsening events, and fewer ralinepag patients reached that point than placebo patients. In the detailed event breakdown, initiation of inhaled or infused prostacyclin occurred as the first event in 2.9% of ralinepag patients and 6.5% of placebo recipients.
For patients, delaying escalation can matter because infusion-based treatment adds pumps, catheters, training and substantial daily treatment burden. The important interpretation is not that oral ralinepag can replace parenteral prostacyclin for every advanced patient, but that effective earlier pathway intensification may postpone the point at which some patients need that next therapeutic step.
The eventual label will be central. If FDA authorizes ralinepag broadly in PAH, physicians will need to determine when it should enter increasingly complex combination regimens and how it should be sequenced against established prostacyclin-pathway agents.
What does the June 24, 2027 PDUFA date put at stake for United Therapeutics?
United Therapeutics is already deeply established in PAH through the treprostinil franchise, giving the company specialist relationships and commercial infrastructure that could support rapid adoption if ralinepag is approved. The candidate would add another route and pharmacological architecture rather than merely another formulation of treprostinil.
The application also arrives as treatment philosophy in PAH shifts toward earlier, more aggressive combination therapy. That trend can expand the opportunity for a tolerable oral prostacyclin-pathway medicine because the relevant commercial question becomes how soon to add pathway intensification rather than whether to reserve it for very advanced disease.
Ralinepag enters review with a particularly persuasive headline number, a 55% reduction in first clinical worsening, but FDA will evaluate what lies beneath that number. The composite was driven predominantly by progression and escalation-related events rather than mortality, while nearly one in five treated patients discontinued because of adverse events. The NDA review therefore concerns not simply whether ralinepag works, but whether once-daily convenience, durable disease control and tolerability combine into a sufficiently attractive long-term treatment profile for patients already receiving substantial PAH therapy.
